Kimberly A Arditte Hall1, Sumaiya E DeLane2, George M Anderson3, Tiffany R Lago4, Rachel Shor2, Weiwei Wang5, Ann M Rasmusson2,6, Suzanne L Pineles2,6. 1. Department of Psychology & Philosophy, Framingham State University, 100 State Street, Framingham, MA, 01701, USA. kardittehall@framingham.edu. 2. National Center for PTSD Women's Health Sciences Division at VA Boston Healthcare System, Boston, MA, 02130, USA. 3. Child Study Center, Yale University School of Medicine, New Haven, CT, 06519, USA. 4. VA Boston Healthcare System, Boston, MA, 02130, USA. 5. MEDKEC Keck Biotechnology Services, Yale University School of Medicine, New Haven, CT, 06519, USA. 6. Department of Psychiatry, Boston University School of Medicine, Boston, MA, 02118, USA.
Abstract
RATIONALE: Aberrations in the stress response are associated with posttraumatic stress disorder (PTSD) symptom development, maintenance, and severity. Gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter, may play a key role in stress recovery. OBJECTIVES: In this preliminary study, we examined whether plasma GABA levels differed between women with PTSD and trauma-exposed healthy controls. METHODS: Thirty participants provided plasma samples during two phases of the menstrual cycle: the early follicular phase and the mid-luteal phase. During each phase, blood was drawn after 45 min of rest, and after mild and moderately stressful psychophysiological tasks. Plasma GABA levels were measured using HPLC-mass spectrometry (LC-MS/MS). RESULTS: In analyses using PTSD diagnosis as a categorical group variable, women with and without a diagnosis of PTSD did not differ in plasma GABA levels (ps > .18). However, in analyses examining PTSD symptom severity as a continuous variable, there was a trend-level positive association between more severe PTSD symptoms and higher plasma GABA levels across the four blood draws (p = .06). In analyses examining DSM-IV PTSD symptom clusters separately, dysphoria symptoms were positively and significantly associated with plasma GABA levels (p = .03). Similarly, there was a trend-level positive association between avoidance cluster symptoms and plasma GABA levels (p = .06). Plasma GABA levels were not modulated by experimentally induced stress or menstrual cycle phase. CONCLUSIONS: Dysregulation in GABA may be a neurobiological marker and/or potential treatment target for women with PTSD symptom profiles characterized by prominent dysphoria and avoidance cluster symptoms.
RATIONALE: Aberrations in the stress response are associated with posttraumatic stress disorder (PTSD) symptom development, maintenance, and severity. Gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter, may play a key role in stress recovery. OBJECTIVES: In this preliminary study, we examined whether plasma GABA levels differed between women with PTSD and trauma-exposed healthy controls. METHODS: Thirty participants provided plasma samples during two phases of the menstrual cycle: the early follicular phase and the mid-luteal phase. During each phase, blood was drawn after 45 min of rest, and after mild and moderately stressful psychophysiological tasks. Plasma GABA levels were measured using HPLC-mass spectrometry (LC-MS/MS). RESULTS: In analyses using PTSD diagnosis as a categorical group variable, women with and without a diagnosis of PTSD did not differ in plasma GABA levels (ps > .18). However, in analyses examining PTSD symptom severity as a continuous variable, there was a trend-level positive association between more severe PTSD symptoms and higher plasma GABA levels across the four blood draws (p = .06). In analyses examining DSM-IV PTSD symptom clusters separately, dysphoria symptoms were positively and significantly associated with plasma GABA levels (p = .03). Similarly, there was a trend-level positive association between avoidance cluster symptoms and plasma GABA levels (p = .06). Plasma GABA levels were not modulated by experimentally induced stress or menstrual cycle phase. CONCLUSIONS: Dysregulation in GABA may be a neurobiological marker and/or potential treatment target for women with PTSD symptom profiles characterized by prominent dysphoria and avoidance cluster symptoms.
Authors: Ann M Rasmusson; Graziano Pinna; Prashni Paliwal; David Weisman; Christopher Gottschalk; Dennis Charney; John Krystal; Alessandro Guidotti Journal: Biol Psychiatry Date: 2006-08-24 Impact factor: 13.382
Authors: Suzanne L Pineles; Yael I Nillni; Matthew W King; Samantha C Patton; Margaret R Bauer; Sheeva M Mostoufi; Megan R Gerber; Richard Hauger; Patricia A Resick; Ann M Rasmusson; Scott P Orr Journal: J Abnorm Psychol Date: 2016-02-11
Authors: Lars Michels; Thomas Schulte-Vels; Matthis Schick; Ruth L O'Gorman; Thomas Zeffiro; Gregor Hasler; Christoph Mueller-Pfeiffer Journal: Psychiatry Res Date: 2014-09-28 Impact factor: 3.222
Authors: Remmelt R Schür; Marco P Boks; Elbert Geuze; Hubertus C Prinsen; Nanda M Verhoeven-Duif; Marian Joëls; René S Kahn; Eric Vermetten; Christiaan H Vinkers Journal: Psychoneuroendocrinology Date: 2016-08-17 Impact factor: 4.905
Authors: Isabelle M Rosso; Melissa R Weiner; David J Crowley; Marisa M Silveri; Scott L Rauch; J Eric Jensen Journal: Depress Anxiety Date: 2013-07-16 Impact factor: 6.505
Authors: Angela Satriano; Alessandro Varrica; Alessandro Frigiola; Alessandro Graziosi; Caterina Di Battista; Adele Patrizia Primavera; Giacomo Centini; Antonio Maconi; Chiara Strozzi; Antonio D W Gavilanes; Luc J Zimmermann; Hans J S Vles; Diego Gazzolo Journal: Diagnostics (Basel) Date: 2021-06-24